Business Wire

Lone Star Funds (“Lone Star”) announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the purchase of a 175-room hotel in Yokohama, Japan from Singapore based real estate development, investment, capital and property management company, Mapletree Investments Pte Ltd, in a transaction advised by JLL. The hotel opened in November 2020 as part of a 1.8 million square foot mixed-use redevelopment project led by Mitsui Fudosan Co. Ltd., and occupies floors 46 through 51 in a condominium tower with over 1,176 high-end residential units. It has direct access to a subway station and is located on the waterfront of Yokohama’s Minato-Mirai submarket. Yokohama is Japan’s second largest city with 3.8 million residents and has strong demand drivers including a new central business district focused on research & development, large international meetings, incentives, conferences, and exhibitions facilities, a professional baseball team stadium, concert arenas, a

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases and develop new antibody linker technologies, will release promising new data for two of its pipeline products at the 2025 Annual American Association for Cancer Research (AACR) meeting in Chicago, Illinois. Furthermore, a joint poster presentation with Oncodesign Services (www.oncodesign-services.com) will highlight the applicability of its antibody conjugation technology, AbYlink™, in the preparation of conjugates for use in non-invasive preclinical imaging. Comprehensive preclinical results will be presented for Debio 1562M, a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 soon to undergo first-in-human evaluation. Two preclinical data releases will be included in the poster display sessions for Debio 0123, a selective WEE1 kinase inhibitor disrupting the DNA-damage

3Degrees, a leading global climate solutions provider and certified B Corporation, is pleased to announce the appointment of Philippe Vedrenne as Chief Executive Officer (CEO), effective May 1, 2025. Vedrenne is moving into the role as 3Degrees’ current CEO and co-founder Steve McDougal steps away from leadership of the company. McDougal informed the Board of Directors last year that he would be retiring as CEO; he will maintain his involvement as a member of the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422978066/en/ 3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025 Vedrenne brings over two decades of global energy market experience operating across multiple continents. Most recently, at Engie, he oversaw trading and retail activities in North and South America for electricity and gas. In this position, he led efforts to bring utility-scale renewable energy solutions to the

Global supply chain solutions leader AIT Worldwide Logistics has finalized an agreement to purchase the assets of GSDMIA, Inc. (“GSDMIA”), an international freight forwarder based in Miami. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422511696/en/ The agreement to purchase GSDMIA's assets boosts AIT's specialized service expertise for the cosmetics, industrial and technology sectors. According to AIT’s Chief Development Officer, Ray Fennelly, who guided the acquisition process, GSDMIA provides deep international experience with air and ocean transportation. The team ships a diverse range of commodities between the United States, Asia, Europe and Latin America, including packaging and finished goods for the cosmetics industry, commercial HVAC equipment, and cryptocurrency data servers. “GSDMIA is an extremely dynamic group that shares AIT’s focus on delivering a world-class customer experience,” Fennelly added. “I'm del

The Kuwait Pavilion at Expo 2025 Osaka, Kansai, Japan, officially opened its doors today, unveiling a spectacular architectural landmark that embodies the country’s bold vision for the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422295094/en/ The Kuwait Pavilion at Expo 2025 Osaka (Photo: AETOSWire) Designed as a “Visionary Lighthouse”, the pavilion stands as a dynamic symbol of the ambitious national development plan, New Kuwait 2035, seamlessly integrating the nation’s rich heritage, innovation, and sustainability in a transformative visitor experience that engages audiences from around the world. Located in the “Empowering Lives” district, the pavilion’s design draws inspiration from Kuwait’s maritime and desert landscapes, reflecting the nation’s journey of resilience, progress, and forward-looking spirit. Kuwait’s participation in Expo 2025 Osaka highlights the continuation of a long-standing relationship

The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Brian Franz as Chief Technology, Data & Analytics Officer, effective April 21, 2025. Mr. Franz will report to President and Chief Executive Officer Stéphane de La Faverie and will join the company’s Executive Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422797613/en/ Brian Franz Appointed Chief Technology, Data & Analytics Officer of The Estée Lauder Companies “As we drive our bold Beauty Reimagined vision, Brian’s deep expertise and fresh perspectives will be pivotal in executing the biggest technology and operational transformation in our company’s history,” said Mr. de La Faverie. “Brian’s experience in modernizing infrastructure, building resilient and sustainable platforms, and advancing AI-driven capabilities will be critical as we accelerate our evolution into a more agile and consumer-focused organization. Brian’s strategic leade

McCauley Propeller Systems announced today its newest C780 propeller for the Beechcraft King Air B300 series, featuring four aluminum swept blades and a 105-inch diameter, has successfully achieved certification from the National Civil Aviation Agency of Brazil (ANAC). Brazil is the second largest installed base globally for Beechcraft King Air turboprops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421372168/en/ McCauley Propeller Systems announced today its newest C780 propeller for the Beechcraft King Air B300 series, featuring four aluminum swept blades and a 105-inch diameter, has successfully achieved certification from the National Civil Aviation Agency of Brazil (ANAC). (Textron Aviation) McCauley Propeller Systems is a division of Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. "The high-performance McCauley C780 propeller, with its lightweight scimitar blade design, will improve the flying experien

Sports company PUMA has achieved its goal of making 9 out of 10 products from recycled or certified materials in 2024 and made further progress in its focus areas circularity, climate and human rights, the company said as part of its sustainability report which was published on Tuesday. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422813225/en/ Sports company PUMA has achieved its goal of making 9 out of 10 products from recycled or certified materials in 2024 and made further progress in its focus areas circularity, climate and human rights, the company said as part of its sustainability report which was published on Tuesday. Since initially setting the goal of 9 out of 10 products in 2021, PUMA has sharply increased the use of recycled and certified materials, which emit fewer greenhouse gases. In 2024, PUMA used 13% recycled cotton and about 75% of recycled polyester fabric in its products. “Reaching our goal of 9 ou

Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, is pleased to announce it has received a Letter of Interest from the Export-Import Bank of the United States (EXIM), for a debt funding package of $300 million. The funding would advance the development of the company’s first industrial-scale lithium metal vanadium battery manufacturing facility. Based on preliminary information regarding expected U.S. exports and jobs supported by the project, EXIM will consider financing up to $300 million of the project’s costs with a repayment term of 12 years under EXIM’s Make More in America initiative (MMIA). MMIA aims to strengthen U.S. manufacturing, particularly in sectors vital to national security, by providing financial support to export-oriented domestic projects. EXIM’s initiative seeks to revitalize American manufacturing, enhance supply chain resilience and level the playing field for U.S. companies in global markets. Pur

Veracode, a global leader in application risk management, today unveiled new capabilities offering proactive risk mitigation and automated security at enterprise scale. With software supply chain attacks and open-source vulnerabilities at an all-time high, enhanced Veracode Risk Manager (VRM) and an early access program for Veracode Package Firewall come at a critical juncture. The innovations represent a significant milestone in Veracode’s vision to deliver centralized risk visibility and secure development from the start. “Security teams face immense pressure to combat evolving threats, while developers require the flexibility to innovate quickly,” said Derek Maki, Head of Product at Veracode. “Our latest Application Risk Management platform enhancements provide organizations with the tools to not just identify risks, but to trace them to their root cause and prevent them before they compromise the software supply chain—all without slowing down development.” Veracode’s newest offerin

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, which already includes discovery pathways for both activated and memory B-cells. The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while accessing broader, deeper data to inform their decision-making. “This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,” said John Kenney, Phd, co-founder and president of Antibody Solutions. “Now, we can capture the entire antigen-specific B-cell repertoire from an immune host by using the hybridoma, mem

Sun Nuclear, a Mirion Medical company, announced today that its SunCHECK® Quality Management software and key radiation therapy Quality Assurance (QA) devices have been awarded CE Class IIb certification under the European Medical Devices Regulation 2017/745 (EU MDR). The transition to EU MDR Class IIb recognizes the safety and performance of Sun Nuclear solutions and confirms compliance with stringent safety requirements. Sun Nuclear solutions awarded Class IIb certification include: The SunCHECK® Platform, a comprehensive software application facilitating essential Patient and Machine QA workflows and centralized data management; Patient-specific QA solutions, including the ArcCHECK®, ArcCHECK®-MR, MapCHECK® 3 and SRS MapCHECK® devices, for measurement of radiation dose distributions against planned doses; Machine QA solutions, including the Daily QA™ 3, Daily QA™ 3-MR, IC PROFILER™, IC PROFILER™-MR devices, for routine QA of linear accelerators used in treatment delivery; and Beam D

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on track to disclose top-line 6-week primary endpoint results in late June. “Completing dosing of all participants in Part A of our 005 trial marks a critical milestone in our mission to address the pressing unmet need in treatment resistant depression,” said Kabir Nath, CEO Compass Pathways. “We are proud of this achievement which reflects our team’s commitment to scientific rigor, operational excellence and potential to deliver a new treatment option to patients who have long been underserved. We are incredibly grateful to the partic

With the recent update of its Document Reader SDK, Regula became the first identity verification (IDV) vendor to make it possible to verify all the dynamic security features of documents in real time. With the latest addition of Dynaprint® checks, the solution ensures more robust physical document authentication during remote onboarding. The innovation has arrived at a time when 58% of businesses globally face fake or modified IDs during digital onboarding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422724077/en/ Dynaprint in the Arizona’s driver’s license (Photo: Regula) Dynaprint® is a dynamic security feature consisting of two different images printed with lenticular technology. Depending on the angle of observation, only one image is visible at a time. Like all other dynamic security features, Dynaprint is crucial for securing identity documents from tampering, since it’s a tricky task to fake it without special e

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual Meeting (AACR) 2025 being held in Chicago April 25-30, 2025. In the poster, entitled “Preferential tumor uptake and retention of EGL-001, an anti-CTLA4-IL2 mutein fusion antibody achieving selective tumor Treg depletion”. Egle Therapeutics unveils preclinical biodistribution data on EGL-001, a novel anti-CTLA4-IL2 mutein fusion antibody designed to selectively deplete tumor-infiltrating regulatory T cells (Tregs). EGL-001 mode of action combines competitive inhibition of IL-2 signaling and potent downregulation of surface CD25, leading to induction of Treg apoptosis. In vivo EGL-001 preferentially bound to the surface of Tregs due to their high CTLA-4 and CD25 expression and depleted them from the tumor microenvironment without affecting other immun

Malaria is one of the world’s most deadly diseases, and it is becoming more pervasive – despite decades of effort and some successes on the path to eradicating it. According to the World Health Organization (WHO), malaria infected 263 million people and killed nearly 600,000 people in 2023 – 75% of whom were children under the age of 5. Of those afflicted, 94% are in Africa – where malaria crushes communities and can cripple economies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422328472/en/ Syngenta Vector Control: A leading role in the prevention of vector-borne disease transmission through its portfolio of mosquito control products Spread by parasites in infected mosquitoes that are highly adept at evolving, malaria’s rise reflects the reality of insecticide resistance and the difficulties developing new solutions. The effective control of mosquitoes remains a key strategy for reducing disease transmission. Syngent

Electricity from renewable sources has become the new normal – in Germany alone, around 60 percent of net electricity generation came from renewables in 2024. But the growing volume of green power is posing new challenges for energy supply: The integration into the existing system urgently requires more flexibility. A Euroelectric/EY study forecasts a doubling of daily European flexibility demand by 2030 compared to 2021, potentially reaching 1.8 TWh daily (137 TWh annually), a substantial rise from the prior 1.5 TWh weekly demand. Electric vehicle (EV) batteries are identified as a key flexibility solution, potentially offering around 116 TWh capacity within five years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417476684/en/ A special exhibition at The smarter E Europe is dedicated to bidirectional charging. ©Solar Promotion GmbH Dr. Frank Spennemann, Senior Manager Charging Solutions Energy at Mercedes-Benz, has a

IFF (NYSE: IFF) Pharma Solutions is excited to announce its participation at Vitafoods™ Europe 2025, the premier global nutraceutical event. The team will showcase its cutting-edge dietary supplement plant-based ingredients portfolio of innovative and trusted brands including SeaGel®, VERDIGEL™ SC, GRINDSTED® Pectin Premium, Ac-Di-Sol®, Avicel®, Accelerate®, and METHOCEL™ in hall 4 at booth 4F25, May 20-22, at the Fira Barcelona Gran Via. "We are excited to highlight vivid examples of how our high-quality functional ingredients and technical expertise help our customers produce superior supplements," said Firat Nalbantoglu, EMEA commercial leader, IFF Pharma Solutions. "Our technical and commercial experts look forward to offering solutions for formulation and processing challenges. If you aim to enhance efficacy and bioavailability in your dietary supplements, we invite you to discover new possibilities with us." IFF Pharma Solutions is committed to advancing the dietary supplement in

Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM’s ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes. Following a rigorous review by the Clinical Laboratory Evaluation Program (CLEP), the Department of Health has determined that LabPMM meets the required standards and granted approval to offer the FLT3 ITD MRD Assay in New York State. This approval underscores the assay’s robust analytical performance and clinical utility in the detection of MRD in patients with FLT3 ITD-mutated AML. "This milestone reflects our commitment to improve patient lives with precision diagnostics," said Jordan Thornes, V.P. Global Clinical Opera

Venture Global Inc. (“Venture Global”) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $2,500,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 7.50% senior secured notes due 2033 in an aggregate principal amount of $1,250,000,000 (the “2033 Notes”) and (ii) a series of 7.75% senior secured notes due 2035 in an aggregate principal amount of $1,250,000,000 (the “2035 Notes” and, together with the 2033 Notes, the “Notes”). The 2033 Notes will mature on May 1, 2033 and the 2035 Notes will mature on May 1, 2035. VGPL intends to use the net proceeds from the offering to (i) prepay certain amounts outstanding under VGPL’s existing senior secured first lien credit facilities (the “Existing Credit Facilities”) and (ii) pay fees and expenses in connection with the offering. The notes are guaranteed by Venture Global Gator Express, LLC (VGPL’s affiliate). The Notes are secur